IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $760.00.

A number of equities research analysts have recently weighed in on IDXX shares. Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Piper Sandler lowered their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. UBS Group decreased their price objective on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Finally, Citigroup initiated coverage on IDEXX Laboratories in a research note on Wednesday. They issued a “neutral” rating and a $650.00 target price for the company.

Insider Transactions at IDEXX Laboratories

In related news, EVP George Fennell sold 11,345 shares of the company’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president directly owned 9,823 shares in the company, valued at $6,352,730.56. This represents a 53.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the sale, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at $54,975,125.30. The trade was a 21.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 45,957 shares of company stock valued at $29,862,109. Insiders own 0.79% of the company’s stock.

Hedge Funds Weigh In On IDEXX Laboratories

Hedge funds and other institutional investors have recently modified their holdings of the company. Andina Capital Management LLC bought a new position in IDEXX Laboratories during the 1st quarter valued at approximately $310,000. SVB Wealth LLC grew its position in shares of IDEXX Laboratories by 17.4% in the 1st quarter. SVB Wealth LLC now owns 7,335 shares of the company’s stock worth $4,121,000 after buying an additional 1,089 shares during the last quarter. Atlas Brown Inc. increased its stake in shares of IDEXX Laboratories by 20.1% during the first quarter. Atlas Brown Inc. now owns 1,071 shares of the company’s stock valued at $602,000 after buying an additional 179 shares during the period. PKO Investment Management Joint Stock Co increased its stake in shares of IDEXX Laboratories by 6.5% during the first quarter. PKO Investment Management Joint Stock Co now owns 3,300 shares of the company’s stock valued at $1,854,000 after buying an additional 200 shares during the period. Finally, Evolve Private Wealth LLC raised its holdings in shares of IDEXX Laboratories by 3.2% during the first quarter. Evolve Private Wealth LLC now owns 640 shares of the company’s stock valued at $360,000 after acquiring an additional 20 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $589.25 on Monday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $46.80 billion, a PE ratio of 45.08, a price-to-earnings-growth ratio of 3.58 and a beta of 1.72. The business’s 50-day moving average price is $601.30 and its 200-day moving average price is $655.21. IDEXX Laboratories has a 12 month low of $402.85 and a 12 month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.IDEXX Laboratories’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts forecast that IDEXX Laboratories will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.